Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit...
Brief Summary
Official Title: “Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit.”
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)
- Study Type: Observational
- Study Design: Observational Model: Case Control, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective
Intervention(s) in this Clinical Trial
- Drug: Piperacillin/tazobactam and other β-lactam/β-lactamase
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- All patients admitted to or transferred to the SICU.
- Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU.
- Provide written informed consent
Exclusion Criteria:
- Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors.
- Females who are pregnant and breast feeding
- Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours.
- Those who have already been participating other clinical study related with antibiotics.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Wyeth is now a wholly owned subsidiary of Pfizer Industry
Overall Clinical Trial Officials and Contacts
Medical Monitor Study Director Wyeth is now a wholly owned subsidiary of Pfizer
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00167960
Study ID Number: 0910X-101525
ClinicalTrials.gov Identifier: NCT00167960
Health Authority: Korea: Food and Drug Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00167960
